CytomX Therapeutics (CTMX) Construction in Progress (2017 - 2023)
CytomX Therapeutics' (CTMX) quarterly Construction in Progress came in at $368000.0 in Q4 2023, down 47.8% YoY from $705000.0 in Q4 2022, and down 47.8% on a QoQ basis from $705000.0 in Q4 2022.
CytomX Therapeutics (CTMX) Construction in Progress (2017 - 2023) Analysis & Trends
CytomX Therapeutics (CTMX) has 7 years of Construction in Progress data on file, last reported at $368000.0 in Q4 2023.
- Quarterly Construction in Progress fell 47.8% year-over-year to $368000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $368000.0 (down 47.8% YoY) and the FY2023 annual result came in at $368000.0, down 47.8% from the prior year.
- Construction in Progress fell to $368000.0 in Q4 2023, from $705000.0 in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $705000.0 in Q4 2022 to a low of $236000.0 in Q4 2019.
- A 5-year average of $373800.0 and a median of $308000.0 in 2021 frame the typical range for Construction in Progress.
- Annual changes were most pronounced in 2019 — Construction in Progress plunged 69.94% — and 2022, when it surged 128.9%.
- Tracing CTMX's Construction in Progress over 5 years: stood at $236000.0 in 2019, then increased by 6.78% to $252000.0 in 2020, then climbed by 22.22% to $308000.0 in 2021, then surged by 128.9% to $705000.0 in 2022, then tumbled by 47.8% to $368000.0 in 2023.
- The last three Construction in Progress figures came in at $368000.0 (Q4 2023), $705000.0 (Q4 2022), and $308000.0 (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 152.67 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 368,000.00 |
| Dec 31, 2022 | 705,000.00 |
| Dec 31, 2021 | 308,000.00 |
| Dec 31, 2020 | 252,000.00 |
| Dec 31, 2019 | 236,000.00 |
| Dec 31, 2018 | 785,000.00 |
| Dec 31, 2017 | 23,000.00 |